Gastric Cancer

>

Latest News

Efficacy and safety findings from the phase 3 GLOW trial assessing zolbetuximab and CAPOX in CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma were consistent with the phase 3 SPOTLIGHT trial, according to an expert from Weill Cornell Medical College
Zolbetuximab Combo Should be Considered New SOC in Gastric Cancer Subtype

March 23rd 2023

Efficacy and safety findings from the phase 3 GLOW trial assessing zolbetuximab and CAPOX in CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma were consistent with the phase 3 SPOTLIGHT trial, according to an expert from Weill Cornell Medical College

Patients from China with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma can now be treated with tislelizumab plus chemotherapy following its approval.
Chinese Regulators Approve Tislelizumab in Advanced Gastric Adenocarcinoma

March 1st 2023

Phase 3 KEYNOTE-859 trial data favor pembrolizumab plus chemotherapy over chemotherapy alone in the frontline setting for metastatic or unresectable gastric or gastroesophageal junction cancer.
KEYNOTE-859 Supports Pembrolizumab/Chemo in Frontline Gastric Cancer

February 16th 2023

Investigators report benefit in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma treated with first-line zolbetuximab and mFOLFOX6.
Zolbetuximab/Chemo Up Front Yields Benefit in CLDN18.2+ Advanced Gastric/GEJ Cancer

January 20th 2023

HER-Vaxx with standard-of-care chemotherapy yielded benefit in patients with HER2-overexpressing metastatic or advanced gastric/gastroesophaeal junction adenocarcinoma.
HER-Vaxx and Chemo Improves Survival Vs Chemo in HER2+ Gastric/GEJ Cancer

January 20th 2023

Video Interviews
Podcasts

More News